BR112019004892A2 - composição farmacêutica de liberação prolongada de clozapina sob a forma de multiparticulados, e processo para a preparação de uma composição farmacêutica de liberação prolongada de clozapina - Google Patents

composição farmacêutica de liberação prolongada de clozapina sob a forma de multiparticulados, e processo para a preparação de uma composição farmacêutica de liberação prolongada de clozapina

Info

Publication number
BR112019004892A2
BR112019004892A2 BR112019004892A BR112019004892A BR112019004892A2 BR 112019004892 A2 BR112019004892 A2 BR 112019004892A2 BR 112019004892 A BR112019004892 A BR 112019004892A BR 112019004892 A BR112019004892 A BR 112019004892A BR 112019004892 A2 BR112019004892 A2 BR 112019004892A2
Authority
BR
Brazil
Prior art keywords
clozapine
pharmaceutical composition
release pharmaceutical
extended release
preparation
Prior art date
Application number
BR112019004892A
Other languages
English (en)
Inventor
Sehgal Ashish
Singh Balvir
Saxena Mayank
Kansagra Piyush
Patel Rikin
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of BR112019004892A2 publication Critical patent/BR112019004892A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se relaciona com uma composição farmacêutica de liberação prolongada de clozapina. a presente invenção fornece uma composição farmacêutica de liberação prolongada compreendendo clozapina, um revestimento vedante, um revestimento ácido e um revestimento de liberação prolongada. a invenção é particularmente adequada para dispensar uma vez por dia uma formulação farmacêutica oral sólida que libera uma quantidade terapeuticamente eficaz de clozapina durante um período de tempo prolongado.
BR112019004892A 2016-09-17 2017-09-16 composição farmacêutica de liberação prolongada de clozapina sob a forma de multiparticulados, e processo para a preparação de uma composição farmacêutica de liberação prolongada de clozapina BR112019004892A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621031726 2016-09-17
PCT/IB2017/055615 WO2018051292A1 (en) 2016-09-17 2017-09-16 Extended release pharmaceutical composition of clozapine

Publications (1)

Publication Number Publication Date
BR112019004892A2 true BR112019004892A2 (pt) 2019-06-11

Family

ID=61619971

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004892A BR112019004892A2 (pt) 2016-09-17 2017-09-16 composição farmacêutica de liberação prolongada de clozapina sob a forma de multiparticulados, e processo para a preparação de uma composição farmacêutica de liberação prolongada de clozapina

Country Status (9)

Country Link
US (2) US11504336B2 (pt)
EP (1) EP3512521B1 (pt)
AU (1) AU2017328245B2 (pt)
BR (1) BR112019004892A2 (pt)
CA (1) CA3036316A1 (pt)
ES (1) ES2960331T3 (pt)
MX (2) MX2019003010A (pt)
WO (1) WO2018051292A1 (pt)
ZA (1) ZA201902379B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504336B2 (en) * 2016-09-17 2022-11-22 Intas Pharmaceuticals Ltd. Extended release pharmaceutical composition of clozapine
CN109030684B (zh) * 2018-10-29 2021-06-15 湖南洞庭药业股份有限公司 氯氮平片剂药物组合物和制法
US11648207B1 (en) * 2021-12-15 2023-05-16 Intas Pharmaceuticals Ltd. Extended release pharmaceutical composition of Clozapine
US11918590B2 (en) * 2021-12-15 2024-03-05 Intas Pharmaceuticals Ltd. Stable extended release pharmaceutical composition of clozapine
CN115745897B (zh) * 2022-11-09 2024-03-22 武汉科技大学 一种氯氮平重结晶方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
EP2266542A3 (en) 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
ITMI20042232A1 (it) 2004-11-19 2005-02-19 Unihart Corp Composizione farmaceutica contenente clozapina
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007056424A2 (en) 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Controlled-release emulsion compositions
US20080026062A1 (en) 2006-07-31 2008-01-31 Isaac Farr Pharmaceutical compositions including nano-sized active agent
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
EP2416764A4 (en) * 2009-04-09 2013-09-04 Alkermes Pharma Ireland Ltd COMPOSITION FOR ACTIVE COMPOSITION
US11504336B2 (en) * 2016-09-17 2022-11-22 Intas Pharmaceuticals Ltd. Extended release pharmaceutical composition of clozapine
US11648207B1 (en) * 2021-12-15 2023-05-16 Intas Pharmaceuticals Ltd. Extended release pharmaceutical composition of Clozapine

Also Published As

Publication number Publication date
EP3512521A1 (en) 2019-07-24
MX2019003010A (es) 2019-11-28
ES2960331T3 (es) 2024-03-04
MX2022006518A (es) 2022-08-04
EP3512521B1 (en) 2023-08-02
US20200054573A1 (en) 2020-02-20
ZA201902379B (en) 2020-08-26
CA3036316A1 (en) 2018-03-22
US11833253B1 (en) 2023-12-05
EP3512521A4 (en) 2020-04-15
AU2017328245B2 (en) 2023-07-06
WO2018051292A1 (en) 2018-03-22
AU2017328245A1 (en) 2019-03-28
US11504336B2 (en) 2022-11-22

Similar Documents

Publication Publication Date Title
BR112019004892A2 (pt) composição farmacêutica de liberação prolongada de clozapina sob a forma de multiparticulados, e processo para a preparação de uma composição farmacêutica de liberação prolongada de clozapina
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
CO2018008207A2 (es) Composiciones para el cuidado bucal y métodos para utilizar las composiciones
SV2018005621A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
CU20110153A7 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
PH12016500895B1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
CL2018001686A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026)
BR112015011430A2 (pt) composição para liberação imediata e prolongada
IN2012DE00912A (pt)
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
BR112018076215A2 (pt) partículas e composições de nicotina
UY36920A (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral
PE20180039A1 (es) Piroglutamato de vortioxetina
BR112015002275A2 (pt) processos e intermediários para a preparação de inibidores da integrase
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
GT201500038A (es) Composicion de difenidol de liberacion prolongada.
MY195384A (en) Two-Component Composition
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
BR112013028668A2 (pt) formulações de paracetamol de liberação sustentada
PT3236938T (pt) Composições farmacêuticas aquosas tópicas orais de flurbiprofeno e dexpantenol

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]